Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
Adherence
Completion rate
Doravirine
HIV
Post-exposure prophylaxis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
04 Sep 2023
04 Sep 2023
Historique:
received:
18
10
2022
accepted:
17
08
2023
medline:
6
9
2023
pubmed:
5
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
HIV post- exposure prophylaxis (PEP) is a prevention tool for individuals with a recent potential exposure to HIV. Doravirine has been available since 2019 in combination with tenofovir disoproxil fumarate and lamivudine and has not been evaluated as a PEP. DOR/3TC/TDF is our department's most commonly prescribed PEP treatment since 2021. This study evaluates the completion rate of the DOR/3TC/TDF as compared to EVG/c/FTC/TAF for PEP, which was the regimen prescribed until 2020 in our hospital.This retrospective observational study was conducted between January 2020 and September 2021. The subjects included consecutively were adults who consulted for an HIV sexual exposure accident and for whom DOR/3TC/TDF in 2021 or EVG/c/FTC/TAF in 2020 was prescribed. The outcomes were the completion rate to the end of treatment (28 days), the seroconversion rate, and the description of side effects.During the study period, 311 people were included: 140 treated with DOR/3TC/TDF and 171 treated with EVGc/FTC/TAF. Considering subjects with a follow-up visit, the completion rate was 96.8% (90/93) in the DOR/3TC/TDF group, and 94.6% (123/130) in the EVG/c/FTC/TAF group (p-value: 0.53). The number of people lost to follow-up was nearly equivalent in both groups: 27.1% (38/140) in the DOR/3TC/TDF group and 23.4% (40/171) in the EVG/c/FTC/TAF group (p-value: 0.45). A side effect was described for 38% (36/94) in the DOR/3TC/TDF group, and 29.7% (38/128) in the EVG/c/FTC/TAF group. No cases of seroconversion were observed.DOR/3TC/TDF appears to have a similar safety profile to EVG/c/FTC/TAF. Due to its lower cost, it seems to be a treatment option for consideration in the context of HIV-exposure accidents.
Identifiants
pubmed: 37667182
doi: 10.1186/s12879-023-08544-x
pii: 10.1186/s12879-023-08544-x
pmc: PMC10478445
doi:
Substances chimiques
Lamivudine
2T8Q726O95
tenofovir alafenamide
EL9943AG5J
doravirine
913P6LK81M
elvitegravir
4GDQ854U53
Anti-HIV Agents
0
Tenofovir
99YXE507IL
Fumarates
0
Emtricitabine
G70B4ETF4S
Cobicistat
LW2E03M5PG
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
578Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Virus Erad. 2018 Apr 01;4(2):72-79
pubmed: 29682298
HIV Med. 2022 Sep;23(8):849-858
pubmed: 35338549
J Acquir Immune Defic Syndr. 2022 May 1;90(1):27-32
pubmed: 34991141
J Virus Erad. 2018 Oct 01;4(4):215-224
pubmed: 30515300
Clin Infect Dis. 2019 Feb 1;68(4):535-544
pubmed: 30184165
J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19532
pubmed: 25394041
J Antimicrob Chemother. 2019 Apr 1;74(4):1021-1027
pubmed: 30689937
Clin Infect Dis. 2020 Feb 14;70(5):943-946
pubmed: 31804669
J Antimicrob Chemother. 2019 May 1;74(5):1417-1424
pubmed: 30753724
AIDS. 2017 Jun 1;31(9):1291-1295
pubmed: 28301425
J Antimicrob Chemother. 2019 Mar 1;74(3):614-617
pubmed: 30476106
BMC Infect Dis. 2016 Nov 29;16(1):718
pubmed: 27894270
Drugs Context. 2020 Mar 03;9:
pubmed: 32180823
AIDS Rev. 2016 Apr-Jun;18(2):101-11
pubmed: 27196356
HIV Med. 2015 Sep;16(8):519-20
pubmed: 26245890
HIV Med. 2021 Mar;22(3):218-224
pubmed: 33108035
Infect Control Hosp Epidemiol. 2013 Sep;34(9):875-92
pubmed: 23917901
HIV Med. 2014 Jan;15(1):13-22
pubmed: 24007390
Clin Infect Dis. 2015 Oct 15;61(8):1336-41
pubmed: 26123937